Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.
Jörgens G, Bange FC, Mühlradt PF, Pabst R, Maus UA, Tschernig T. Jörgens G, et al. Among authors: muhlradt pf. Inflammation. 2009 Aug;32(4):247-51. doi: 10.1007/s10753-009-9127-1. Inflammation. 2009. PMID: 19543820
Macrophage-activating lipopeptide-2 (MALP-2) induces a localized inflammatory response in rats resulting in activation of brain sites implicated in fever.
Knorr C, Hübschle T, Murgott J, Mühlradt P, Gerstberger R, Roth J. Knorr C, et al. Brain Res. 2008 Apr 18;1205:36-46. doi: 10.1016/j.brainres.2008.02.021. Epub 2008 Feb 21. Brain Res. 2008. PMID: 18353287
MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?
Galanos C, Gumenscheimer M, Mühlradt P, Jirillo E, Freudenberg M. Galanos C, et al. J Endotoxin Res. 2000;6(6):471-6. J Endotoxin Res. 2000. PMID: 11521073
The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN-gamma to reverse the Th2 skew in an in vitro allergy model.
Weigt H, Muhlradt PF, Larbig M, Krug N, Braun A. Weigt H, et al. Among authors: muhlradt pf. J Immunol. 2004 May 15;172(10):6080-6. doi: 10.4049/jimmunol.172.10.6080. J Immunol. 2004. PMID: 15128792
In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.
Lührmann A, Deiters U, Skokowa J, Hanke M, Gessner JE, Mühlradt PF, Pabst R, Tschernig T. Lührmann A, et al. Among authors: muhlradt pf. Infect Immun. 2002 Jul;70(7):3785-92. doi: 10.1128/iai.70.7.3785-3792.2002. Infect Immun. 2002. PMID: 12065522 Free PMC article.
The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.
Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Mühlradt PF, Guzmán CA. Rharbaoui F, et al. Among authors: muhlradt pf. Eur J Immunol. 2002 Oct;32(10):2857-65. doi: 10.1002/1521-4141(2002010)32:10<2857::AID-IMMU2857>3.0.CO;2-R. Eur J Immunol. 2002. PMID: 12355438
Peripheral and central cyclooxygenase (COX) products may contribute to the manifestation of brain-controlled sickness responses during localized inflammation induced by macrophage-activating lipopeptide-2 (MALP-2).
Knorr C, Marks D, Gerstberger R, Mühlradt PF, Roth J, Rummel C. Knorr C, et al. Among authors: muhlradt pf. Neurosci Lett. 2010 Jul 26;479(2):107-11. doi: 10.1016/j.neulet.2010.05.036. Epub 2010 May 16. Neurosci Lett. 2010. PMID: 20580659
Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration.
Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Mühlradt PF, Schieffer B. Grote K, et al. Among authors: muhlradt pf. Blood. 2010 Mar 25;115(12):2543-52. doi: 10.1182/blood-2009-05-224402. Epub 2010 Jan 7. Blood. 2010. PMID: 20056792
The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.
Müller C, Tufa DM, Chatterjee D, Mühlradt PF, Schmidt RE, Jacobs R. Müller C, et al. Among authors: muhlradt pf. Cancer Immunol Immunother. 2015 Sep;64(9):1175-84. doi: 10.1007/s00262-015-1723-3. Epub 2015 Jun 3. Cancer Immunol Immunother. 2015. PMID: 26036909
Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice--a phase I trial in 12 patients.
Niebuhr M, Mühlradt PF, Wittmann M, Kapp A, Werfel T. Niebuhr M, et al. Among authors: muhlradt pf. Exp Dermatol. 2008 Dec;17(12):1052-6. doi: 10.1111/j.1600-0625.2008.00750.x. Exp Dermatol. 2008. PMID: 18713273 Clinical Trial.
100 results
Jump to page